奎瑞通过降低TGF-β1-Smad2/3通路的调节来调节肺高血压中的肺血管重塑
Rui-Juan Gao1,2, Nigala Aikeremu2, Nan Cao3
1Department of Medical Imaging Center, First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, 832002, China.
BMC cardiovascular disorders
|October 4, 2024
概括
奎瑞 (Que) 通过抑制肺血管改造和右心室增生,有效治疗肺动脉高血压 (PAH). 它针对TGF-β1/Smad2/Smad3通路,为PAH提供了潜在的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 肺动脉高血压 (PAH) 是一种进展性疾病.
- 肺血管改造涉及光滑肌肉细胞的增殖和迁移.
- 奎尔 (Que) 显示出对PAH的治疗潜力,但其机制尚不清楚.
研究的目的:
- 为了研究奎尔丁对PAH肺血管改造的作用.
- 阐明奎尔丁在治疗PAH中的分子机制.
主要方法:
- 在使用单克罗他林 (MCT) 的老鼠和在人类肺动脉光滑肌细胞 (HPASMCs) 中诱导了PAH,具有血小板衍生的生生长因子BB (PDGF-BB).
- 分析了增殖和迁移标记物 (PCNA,OPN,α-SMA) 和TGF-β1/Smad2/3通路的表达.
- 奎尔塞丁对这些参数的影响在体内和体外进行了评估.
主要成果:
- 在老鼠中,MCT诱导了右心室壁增生和肺动脉狭窄.
- 奎尔素逆转了MCT诱导的变化,并使蛋白质表达正常化.
- 奎尔赛丁抑制了PDGF-BB诱导的HPASMC增殖和迁移,降低了TGF-β1 / Smad2 / 3通路的调节.
结论:
- 奎尔赛丁抑制HPASMC的增殖,迁移和表型转变.
- 奎尔丁降低了TGF-β1 / Smad2 / Smad3通路的调节.
- 奎尔赛丁可以减少右心室增生和肺血管重塑,为PAH提供潜在的治疗方法.
更多相关视频
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
144
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
144
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
132
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
132